Pharmanutra S.p.A.
PHN.MI · MIL
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.09 | -1.62 | -2.09 |
| FCF Yield | 0.00% | -0.71% | 0.29% | 0.90% |
| EV / EBITDA | 0.71 | 39.59 | 95.78 | 64.98 |
| Quality | ||||
| ROIC | 5.16% | 8.75% | 2.50% | 3.49% |
| Gross Margin | 76.58% | 80.58% | 77.47% | 98.95% |
| Cash Conversion Ratio | 1.72 | -0.36 | 0.86 | 1.92 |
| Growth | ||||
| Revenue 3-Year CAGR | 10.39% | 9.46% | 10.56% | 11.69% |
| Free Cash Flow Growth | 338.03% | -328.15% | -70.62% | -10.77% |
| Safety | ||||
| Net Debt / EBITDA | 0.71 | 1.13 | 0.02 | 1.06 |
| Interest Coverage | 52.22 | 45.64 | 15.76 | 13.09 |
| Efficiency | ||||
| Inventory Turnover | 0.75 | 0.72 | 0.71 | 0.05 |
| Cash Conversion Cycle | -13.73 | -54.12 | -44.61 | -2,286.51 |